Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Oppenheimer Maintains Outperform on Immunovant, Lowers Price Target to $46

Author: Benzinga Newsdesk | June 03, 2024 08:26am

Oppenheimer analyst Leland Gershell maintains Immunovant (NASDAQ:IMVT) with a Outperform and lowers the price target from $50 to $46.

Posted In: IMVT

07/16/2024 Vestis Corporation (VSTS)

07/22/2024 Biogen Inc. (BIIB)

07/23/2024 Fastly, Inc. (FSLY)

08/02/2024 Humana Inc. (HUM)